| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 312 | 2024 | 8037 | 14.810 |
Why?
|
| Amyloid beta-Peptides | 166 | 2024 | 3585 | 9.990 |
Why?
|
| tau Proteins | 86 | 2024 | 1868 | 6.070 |
Why?
|
| Memory | 44 | 2023 | 2174 | 4.780 |
Why?
|
| Amyloid | 41 | 2023 | 795 | 4.340 |
Why?
|
| Positron-Emission Tomography | 155 | 2024 | 6274 | 4.190 |
Why?
|
| Aniline Compounds | 55 | 2021 | 986 | 3.760 |
Why?
|
| Brain | 150 | 2023 | 26413 | 3.750 |
Why?
|
| Memory Disorders | 34 | 2023 | 1184 | 3.640 |
Why?
|
| Hippocampus | 43 | 2020 | 3676 | 3.580 |
Why?
|
| Aging | 68 | 2020 | 8661 | 3.440 |
Why?
|
| Neuropsychological Tests | 96 | 2024 | 6991 | 2.840 |
Why?
|
| Cerebral Cortex | 41 | 2020 | 5709 | 2.790 |
Why?
|
| Mental Recall | 23 | 2020 | 1205 | 2.650 |
Why?
|
| Cognition Disorders | 49 | 2018 | 4041 | 2.650 |
Why?
|
| Nerve Net | 27 | 2019 | 2175 | 2.640 |
Why?
|
| Apolipoprotein E4 | 29 | 2023 | 668 | 2.410 |
Why?
|
| Thiazoles | 45 | 2019 | 1484 | 2.330 |
Why?
|
| Temporal Lobe | 24 | 2023 | 1670 | 2.290 |
Why?
|
| Tauopathies | 8 | 2024 | 307 | 2.290 |
Why?
|
| Magnetic Resonance Imaging | 160 | 2023 | 35423 | 2.260 |
Why?
|
| Amyloidosis | 17 | 2023 | 795 | 2.250 |
Why?
|
| Cognition | 52 | 2024 | 6765 | 2.220 |
Why?
|
| Aged, 80 and over | 187 | 2023 | 57768 | 1.910 |
Why?
|
| Brain Mapping | 47 | 2018 | 6671 | 1.900 |
Why?
|
| Presenilin-1 | 22 | 2023 | 635 | 1.840 |
Why?
|
| Association Learning | 11 | 2015 | 224 | 1.730 |
Why?
|
| Aged | 273 | 2023 | 163253 | 1.630 |
Why?
|
| Plaque, Amyloid | 14 | 2023 | 729 | 1.600 |
Why?
|
| Ethylene Glycols | 12 | 2021 | 156 | 1.590 |
Why?
|
| Dementia | 18 | 2022 | 2518 | 1.520 |
Why?
|
| Carbolines | 12 | 2023 | 265 | 1.510 |
Why?
|
| Clinical Trials as Topic | 26 | 2023 | 7908 | 1.270 |
Why?
|
| Longitudinal Studies | 77 | 2023 | 13990 | 1.240 |
Why?
|
| Entorhinal Cortex | 10 | 2023 | 272 | 1.230 |
Why?
|
| Nootropic Agents | 9 | 2018 | 160 | 1.200 |
Why?
|
| Male | 306 | 2024 | 350027 | 1.200 |
Why?
|
| Amyloidogenic Proteins | 12 | 2023 | 152 | 1.180 |
Why?
|
| Disease Progression | 51 | 2023 | 13280 | 1.180 |
Why?
|
| Awareness | 4 | 2018 | 640 | 1.180 |
Why?
|
| Female | 324 | 2024 | 380197 | 1.180 |
Why?
|
| Neural Pathways | 16 | 2019 | 2972 | 1.150 |
Why?
|
| Humans | 454 | 2024 | 744220 | 1.140 |
Why?
|
| Peptide Fragments | 28 | 2023 | 5096 | 1.130 |
Why?
|
| Apolipoproteins E | 25 | 2023 | 1438 | 1.060 |
Why?
|
| Heterozygote | 22 | 2023 | 2805 | 1.050 |
Why?
|
| Pattern Recognition, Visual | 8 | 2009 | 824 | 1.020 |
Why?
|
| Face | 9 | 2017 | 994 | 0.990 |
Why?
|
| Thiazines | 2 | 2022 | 38 | 0.990 |
Why?
|
| Activities of Daily Living | 14 | 2023 | 2420 | 0.960 |
Why?
|
| Radiopharmaceuticals | 18 | 2020 | 2662 | 0.930 |
Why?
|
| Parietal Lobe | 8 | 2017 | 838 | 0.890 |
Why?
|
| Apathy | 8 | 2019 | 96 | 0.880 |
Why?
|
| Cross-Sectional Studies | 66 | 2024 | 25043 | 0.860 |
Why?
|
| Image Processing, Computer-Assisted | 35 | 2021 | 8950 | 0.850 |
Why?
|
| Loneliness | 4 | 2022 | 185 | 0.800 |
Why?
|
| Amyloid beta-Protein Precursor | 7 | 2021 | 1121 | 0.790 |
Why?
|
| Amyloid Precursor Protein Secretases | 3 | 2021 | 584 | 0.760 |
Why?
|
| Scopolamine | 2 | 2019 | 99 | 0.730 |
Why?
|
| Mental Status Schedule | 14 | 2018 | 321 | 0.720 |
Why?
|
| Atrophy | 19 | 2023 | 1582 | 0.690 |
Why?
|
| Middle Aged | 144 | 2023 | 213367 | 0.690 |
Why?
|
| Diagnostic Self Evaluation | 4 | 2017 | 230 | 0.690 |
Why?
|
| Psychomotor Performance | 10 | 2019 | 1901 | 0.690 |
Why?
|
| Neocortex | 6 | 2017 | 401 | 0.670 |
Why?
|
| Verbal Learning | 5 | 2014 | 466 | 0.670 |
Why?
|
| Cerebral Amyloid Angiopathy | 5 | 2022 | 859 | 0.660 |
Why?
|
| Patient Selection | 13 | 2022 | 4216 | 0.660 |
Why?
|
| Cholinergic Antagonists | 1 | 2019 | 165 | 0.640 |
Why?
|
| Genes, Dominant | 10 | 2018 | 880 | 0.640 |
Why?
|
| Agnosia | 2 | 2018 | 66 | 0.620 |
Why?
|
| Parahippocampal Gyrus | 2 | 2020 | 116 | 0.600 |
Why?
|
| Presenilin-2 | 4 | 2018 | 106 | 0.570 |
Why?
|
| TDP-43 Proteinopathies | 4 | 2020 | 38 | 0.560 |
Why?
|
| National Institute on Aging (U.S.) | 3 | 2018 | 32 | 0.540 |
Why?
|
| Self Report | 7 | 2023 | 3558 | 0.520 |
Why?
|
| Secondary Prevention | 4 | 2021 | 1531 | 0.520 |
Why?
|
| Fluorodeoxyglucose F18 | 14 | 2018 | 2017 | 0.510 |
Why?
|
| Biomedical Research | 9 | 2021 | 3311 | 0.500 |
Why?
|
| Executive Function | 12 | 2020 | 1362 | 0.500 |
Why?
|
| Learning | 7 | 2020 | 1713 | 0.490 |
Why?
|
| Psychiatric Status Rating Scales | 18 | 2018 | 6037 | 0.490 |
Why?
|
| Fluorine Radioisotopes | 5 | 2018 | 449 | 0.480 |
Why?
|
| Early Diagnosis | 10 | 2021 | 1184 | 0.480 |
Why?
|
| Genetic Predisposition to Disease | 17 | 2022 | 17449 | 0.470 |
Why?
|
| Cues | 4 | 2017 | 873 | 0.460 |
Why?
|
| Neurofibrillary Tangles | 5 | 2023 | 439 | 0.460 |
Why?
|
| Judgment | 2 | 2020 | 281 | 0.450 |
Why?
|
| Oxygen | 12 | 2017 | 4187 | 0.400 |
Why?
|
| Locus Coeruleus | 5 | 2023 | 176 | 0.400 |
Why?
|
| Evoked Potentials | 3 | 2007 | 1057 | 0.390 |
Why?
|
| Intelligence | 4 | 2016 | 920 | 0.390 |
Why?
|
| Nerve Degeneration | 5 | 2020 | 748 | 0.390 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2016 | 1372 | 0.380 |
Why?
|
| Advisory Committees | 5 | 2022 | 774 | 0.380 |
Why?
|
| Adult | 84 | 2023 | 214035 | 0.380 |
Why?
|
| Down Syndrome | 1 | 2019 | 880 | 0.370 |
Why?
|
| Clinical Trials, Phase II as Topic | 5 | 2021 | 628 | 0.370 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2011 | 154 | 0.370 |
Why?
|
| Alleles | 5 | 2019 | 6938 | 0.360 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2013 | 271 | 0.360 |
Why?
|
| Reference Values | 12 | 2016 | 4982 | 0.360 |
Why?
|
| Photic Stimulation | 8 | 2016 | 2027 | 0.360 |
Why?
|
| Pyridines | 2 | 2022 | 2822 | 0.360 |
Why?
|
| Asymptomatic Diseases | 5 | 2021 | 552 | 0.350 |
Why?
|
| Linear Models | 17 | 2019 | 5953 | 0.340 |
Why?
|
| Thiadiazines | 2 | 2019 | 10 | 0.330 |
Why?
|
| Prefrontal Cortex | 4 | 2015 | 2148 | 0.330 |
Why?
|
| Benzothiazoles | 6 | 2017 | 248 | 0.330 |
Why?
|
| Lewy Body Disease | 2 | 2024 | 229 | 0.320 |
Why?
|
| Association | 2 | 2011 | 53 | 0.320 |
Why?
|
| Corpus Striatum | 3 | 2019 | 1220 | 0.310 |
Why?
|
| Gyrus Cinguli | 6 | 2018 | 1091 | 0.310 |
Why?
|
| Antipsychotic Agents | 3 | 2018 | 3058 | 0.300 |
Why?
|
| Intelligence Tests | 3 | 2007 | 505 | 0.290 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2007 | 147 | 0.290 |
Why?
|
| Names | 3 | 2017 | 50 | 0.290 |
Why?
|
| Multifactorial Inheritance | 3 | 2019 | 1194 | 0.270 |
Why?
|
| Cohort Studies | 34 | 2023 | 40559 | 0.270 |
Why?
|
| Carrier State | 2 | 2021 | 518 | 0.260 |
Why?
|
| Risk | 12 | 2021 | 9685 | 0.260 |
Why?
|
| Receptors, AMPA | 1 | 2007 | 331 | 0.260 |
Why?
|
| Rest | 3 | 2017 | 901 | 0.250 |
Why?
|
| Young Adult | 27 | 2020 | 56436 | 0.250 |
Why?
|
| Age Factors | 15 | 2018 | 18367 | 0.250 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2018 | 422 | 0.250 |
Why?
|
| Mutation | 19 | 2023 | 29784 | 0.250 |
Why?
|
| Sex Characteristics | 5 | 2023 | 2586 | 0.250 |
Why?
|
| Autoantibodies | 1 | 2013 | 2038 | 0.250 |
Why?
|
| Attention | 4 | 2013 | 2399 | 0.250 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2021 | 840 | 0.240 |
Why?
|
| Semantics | 2 | 2019 | 584 | 0.240 |
Why?
|
| Genetic Association Studies | 5 | 2020 | 2702 | 0.240 |
Why?
|
| Drug Evaluation | 2 | 2016 | 637 | 0.240 |
Why?
|
| Research Design | 6 | 2023 | 5987 | 0.240 |
Why?
|
| Double-Blind Method | 12 | 2021 | 12035 | 0.230 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2012 | 943 | 0.230 |
Why?
|
| Risk Factors | 24 | 2023 | 72280 | 0.230 |
Why?
|
| Apolipoprotein E3 | 2 | 2022 | 97 | 0.230 |
Why?
|
| Follow-Up Studies | 26 | 2021 | 39045 | 0.230 |
Why?
|
| Organ Size | 7 | 2018 | 2252 | 0.220 |
Why?
|
| Societies, Medical | 3 | 2011 | 3741 | 0.220 |
Why?
|
| Reference Standards | 1 | 2006 | 1025 | 0.220 |
Why?
|
| Vaginal Diseases | 2 | 1995 | 102 | 0.220 |
Why?
|
| Biphenyl Compounds | 1 | 2007 | 914 | 0.210 |
Why?
|
| Hypoxanthines | 1 | 2002 | 35 | 0.210 |
Why?
|
| Neurodegenerative Diseases | 5 | 2019 | 1062 | 0.210 |
Why?
|
| Age of Onset | 8 | 2018 | 3270 | 0.210 |
Why?
|
| Nerve Tissue Proteins | 4 | 2023 | 4465 | 0.210 |
Why?
|
| Educational Status | 5 | 2023 | 2539 | 0.210 |
Why?
|
| Learning Curve | 1 | 2023 | 208 | 0.210 |
Why?
|
| Verbal Behavior | 2 | 2012 | 339 | 0.210 |
Why?
|
| Cyclic S-Oxides | 2 | 2019 | 21 | 0.200 |
Why?
|
| Independent Living | 3 | 2021 | 568 | 0.200 |
Why?
|
| Concept Formation | 1 | 2002 | 158 | 0.190 |
Why?
|
| Genotype | 13 | 2021 | 12956 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 5 | 2023 | 9275 | 0.190 |
Why?
|
| Feasibility Studies | 4 | 2023 | 5076 | 0.190 |
Why?
|
| Truth Disclosure | 2 | 2020 | 436 | 0.190 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2002 | 156 | 0.180 |
Why?
|
| Anxiety | 4 | 2018 | 4297 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 2727 | 0.180 |
Why?
|
| Depression | 7 | 2019 | 7767 | 0.180 |
Why?
|
| Limbic System | 2 | 2017 | 426 | 0.180 |
Why?
|
| Statistics as Topic | 4 | 2016 | 2374 | 0.180 |
Why?
|
| Cognitive Reserve | 1 | 2020 | 76 | 0.180 |
Why?
|
| Widowhood | 1 | 2020 | 54 | 0.180 |
Why?
|
| Models, Neurological | 4 | 2020 | 1775 | 0.180 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2021 | 311 | 0.180 |
Why?
|
| Social Perception | 1 | 2003 | 424 | 0.180 |
Why?
|
| Predictive Value of Tests | 12 | 2018 | 15070 | 0.170 |
Why?
|
| Glucuronidase | 1 | 2021 | 207 | 0.170 |
Why?
|
| Occipital Lobe | 2 | 2020 | 380 | 0.170 |
Why?
|
| Fornix, Brain | 1 | 2019 | 70 | 0.170 |
Why?
|
| Multiple Sclerosis | 3 | 2022 | 3079 | 0.170 |
Why?
|
| Cerebral Amyloid Angiopathy, Familial | 1 | 2019 | 53 | 0.170 |
Why?
|
| Reproducibility of Results | 11 | 2023 | 19907 | 0.170 |
Why?
|
| Amnesia | 1 | 2001 | 248 | 0.170 |
Why?
|
| Luteal Phase | 1 | 2019 | 147 | 0.170 |
Why?
|
| Ethics, Research | 1 | 2021 | 191 | 0.170 |
Why?
|
| Aphasia, Primary Progressive | 1 | 2020 | 73 | 0.170 |
Why?
|
| Follicular Phase | 1 | 2019 | 153 | 0.170 |
Why?
|
| Trigeminal Caudal Nucleus | 1 | 2018 | 18 | 0.170 |
Why?
|
| Neurofilament Proteins | 1 | 2021 | 318 | 0.170 |
Why?
|
| Receptors, Immunologic | 2 | 2015 | 1423 | 0.170 |
Why?
|
| Research Subjects | 1 | 2020 | 239 | 0.160 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2019 | 99 | 0.160 |
Why?
|
| Purines | 1 | 2002 | 594 | 0.160 |
Why?
|
| Colombia | 4 | 2021 | 258 | 0.160 |
Why?
|
| Telephone | 2 | 2019 | 617 | 0.160 |
Why?
|
| Spouses | 1 | 2021 | 286 | 0.160 |
Why?
|
| Computers | 1 | 2021 | 611 | 0.160 |
Why?
|
| Brain Edema | 5 | 2013 | 617 | 0.150 |
Why?
|
| Regression Analysis | 7 | 2015 | 6461 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 3 | 2011 | 7281 | 0.150 |
Why?
|
| Contrast Media | 3 | 2019 | 5300 | 0.150 |
Why?
|
| Emotions | 1 | 2009 | 2659 | 0.150 |
Why?
|
| Reaction Time | 3 | 2023 | 2102 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2023 | 9960 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2007 | 1940 | 0.150 |
Why?
|
| Immunoassay | 2 | 2018 | 752 | 0.150 |
Why?
|
| Social Participation | 1 | 2019 | 173 | 0.150 |
Why?
|
| Public-Private Sector Partnerships | 2 | 2014 | 121 | 0.150 |
Why?
|
| Socioeconomic Factors | 4 | 2020 | 7784 | 0.150 |
Why?
|
| Seizures | 2 | 2020 | 2859 | 0.140 |
Why?
|
| Zidovudine | 2 | 1998 | 620 | 0.140 |
Why?
|
| Analysis of Variance | 5 | 2015 | 6367 | 0.140 |
Why?
|
| Olfactory Perception | 1 | 2016 | 54 | 0.140 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 6 | 2019 | 1107 | 0.140 |
Why?
|
| Life Style | 2 | 2020 | 3835 | 0.140 |
Why?
|
| Lipoxygenase Inhibitors | 3 | 1994 | 94 | 0.140 |
Why?
|
| Severity of Illness Index | 14 | 2018 | 15538 | 0.140 |
Why?
|
| Visual Cortex | 4 | 2016 | 1149 | 0.140 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2018 | 3328 | 0.140 |
Why?
|
| Body Mass Index | 3 | 2020 | 12718 | 0.140 |
Why?
|
| Dominance, Cerebral | 2 | 2009 | 635 | 0.140 |
Why?
|
| Cervix Uteri | 1 | 2019 | 590 | 0.130 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 170 | 0.130 |
Why?
|
| Amyloid Neuropathies | 1 | 2014 | 15 | 0.130 |
Why?
|
| Health | 1 | 2018 | 394 | 0.130 |
Why?
|
| Community-Based Participatory Research | 1 | 2017 | 214 | 0.130 |
Why?
|
| Carotid Artery Diseases | 1 | 2022 | 882 | 0.130 |
Why?
|
| Choroid Plexus | 1 | 2018 | 231 | 0.130 |
Why?
|
| Motor Activity | 2 | 2015 | 2714 | 0.130 |
Why?
|
| Task Performance and Analysis | 3 | 2017 | 780 | 0.130 |
Why?
|
| Functional Laterality | 2 | 2013 | 2290 | 0.120 |
Why?
|
| Adolescent | 20 | 2022 | 85759 | 0.120 |
Why?
|
| Tongue | 1 | 2017 | 406 | 0.120 |
Why?
|
| Carbon Radioisotopes | 2 | 2013 | 592 | 0.120 |
Why?
|
| Cooperative Behavior | 3 | 2016 | 1504 | 0.120 |
Why?
|
| Longevity | 1 | 2022 | 1069 | 0.120 |
Why?
|
| Membrane Glycoproteins | 2 | 2015 | 3769 | 0.120 |
Why?
|
| Australia | 3 | 2022 | 1169 | 0.120 |
Why?
|
| Cardiovascular Diseases | 4 | 2022 | 15161 | 0.120 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 502 | 0.120 |
Why?
|
| Hydroxyurea | 2 | 1992 | 290 | 0.120 |
Why?
|
| Neurons | 3 | 2011 | 9335 | 0.120 |
Why?
|
| Psychometrics | 6 | 2023 | 3002 | 0.120 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 1998 | 1320 | 0.120 |
Why?
|
| Sex Factors | 4 | 2019 | 10396 | 0.120 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2016 | 1537 | 0.120 |
Why?
|
| Hip Fractures | 1 | 2002 | 955 | 0.120 |
Why?
|
| Hallucinations | 2 | 2013 | 360 | 0.120 |
Why?
|
| Case-Control Studies | 10 | 2020 | 21752 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2017 | 4044 | 0.120 |
Why?
|
| Membrane Proteins | 3 | 2020 | 7879 | 0.120 |
Why?
|
| Enzyme Inhibitors | 2 | 2021 | 3800 | 0.110 |
Why?
|
| Program Development | 1 | 2020 | 1315 | 0.110 |
Why?
|
| Disclosure | 2 | 2016 | 736 | 0.110 |
Why?
|
| Bayes Theorem | 2 | 2023 | 2309 | 0.110 |
Why?
|
| Inflammation | 1 | 2013 | 10634 | 0.110 |
Why?
|
| Information Dissemination | 3 | 2016 | 1100 | 0.110 |
Why?
|
| Teaching | 1 | 2021 | 1174 | 0.110 |
Why?
|
| Delirium | 2 | 2019 | 1609 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2018 | 3533 | 0.110 |
Why?
|
| Olfaction Disorders | 1 | 2015 | 222 | 0.110 |
Why?
|
| Animals | 21 | 2023 | 168788 | 0.110 |
Why?
|
| Visual Pathways | 1 | 2016 | 565 | 0.110 |
Why?
|
| Cerebrum | 1 | 2013 | 137 | 0.100 |
Why?
|
| Alcoholism | 1 | 2023 | 1906 | 0.100 |
Why?
|
| Stilbenes | 1 | 2013 | 156 | 0.100 |
Why?
|
| Genomics | 2 | 2012 | 5722 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2021 | 2682 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 1998 | 2026 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2015 | 1677 | 0.100 |
Why?
|
| Uterine Cervical Diseases | 1 | 1992 | 77 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 6485 | 0.100 |
Why?
|
| Models, Chemical | 1 | 2014 | 626 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 1152 | 0.100 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2017 | 720 | 0.100 |
Why?
|
| Postoperative Complications | 4 | 2019 | 15294 | 0.100 |
Why?
|
| Genetic Variation | 2 | 2020 | 6546 | 0.100 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 1504 | 0.100 |
Why?
|
| Chromosome Disorders | 1 | 2014 | 515 | 0.100 |
Why?
|
| Neuropeptides | 1 | 2017 | 942 | 0.100 |
Why?
|
| Logistic Models | 5 | 2018 | 13409 | 0.100 |
Why?
|
| Mass Screening | 3 | 2020 | 5252 | 0.100 |
Why?
|
| Apolipoprotein E2 | 2 | 2023 | 127 | 0.100 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2012 | 197 | 0.100 |
Why?
|
| Health Policy | 2 | 2014 | 2661 | 0.100 |
Why?
|
| Brain Chemistry | 3 | 2015 | 982 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2020 | 15525 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 4 | 2022 | 2647 | 0.100 |
Why?
|
| Diffusion Tensor Imaging | 5 | 2020 | 2305 | 0.090 |
Why?
|
| Microcirculation | 1 | 2015 | 1286 | 0.090 |
Why?
|
| Inositol | 1 | 2011 | 218 | 0.090 |
Why?
|
| Geriatric Assessment | 4 | 2016 | 1372 | 0.090 |
Why?
|
| Radioisotopes | 1 | 2012 | 499 | 0.090 |
Why?
|
| Individuality | 2 | 2014 | 307 | 0.090 |
Why?
|
| Homozygote | 3 | 2022 | 1786 | 0.090 |
Why?
|
| Intestinal Diseases | 1 | 1995 | 531 | 0.090 |
Why?
|
| Cerebral Infarction | 1 | 2015 | 1010 | 0.090 |
Why?
|
| Placebos | 2 | 2007 | 1677 | 0.090 |
Why?
|
| Brain Diseases | 2 | 2019 | 1564 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 2016 | 1312 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2017 | 831 | 0.090 |
Why?
|
| Prospective Studies | 11 | 2023 | 53280 | 0.090 |
Why?
|
| Retrospective Studies | 12 | 2020 | 77426 | 0.090 |
Why?
|
| Treatment Outcome | 12 | 2021 | 63119 | 0.090 |
Why?
|
| Cerebrospinal Fluid | 1 | 2012 | 534 | 0.090 |
Why?
|
| Tumor Virus Infections | 1 | 1992 | 452 | 0.080 |
Why?
|
| Genome-Wide Association Study | 8 | 2023 | 12264 | 0.080 |
Why?
|
| Preventive Medicine | 1 | 2011 | 263 | 0.080 |
Why?
|
| Models, Theoretical | 2 | 2018 | 3591 | 0.080 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2010 | 768 | 0.080 |
Why?
|
| Laser Therapy | 2 | 1993 | 1072 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2018 | 1582 | 0.080 |
Why?
|
| Prognosis | 10 | 2022 | 29050 | 0.080 |
Why?
|
| Antibodies, Antinuclear | 1 | 1989 | 326 | 0.080 |
Why?
|
| Mood Disorders | 1 | 2015 | 1106 | 0.080 |
Why?
|
| Phosphorylation | 5 | 2018 | 8437 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2000 | 2279 | 0.080 |
Why?
|
| Time Factors | 9 | 2018 | 40063 | 0.080 |
Why?
|
| Internationality | 1 | 2013 | 1003 | 0.080 |
Why?
|
| Prosopagnosia | 1 | 2008 | 60 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 2867 | 0.080 |
Why?
|
| Autoantigens | 2 | 2003 | 892 | 0.080 |
Why?
|
| Fluorouracil | 1 | 1992 | 1616 | 0.070 |
Why?
|
| Prevalence | 4 | 2022 | 15226 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2017 | 1859 | 0.070 |
Why?
|
| Educational Measurement | 1 | 2014 | 1209 | 0.070 |
Why?
|
| Principal Component Analysis | 3 | 2017 | 940 | 0.070 |
Why?
|
| Sensitivity and Specificity | 7 | 2018 | 14726 | 0.070 |
Why?
|
| Myositis | 1 | 1989 | 251 | 0.070 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 279 | 0.070 |
Why?
|
| United States | 12 | 2024 | 69867 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2021 | 23337 | 0.070 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 18027 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2015 | 1161 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 2422 | 0.070 |
Why?
|
| Genetic Markers | 1 | 2012 | 2634 | 0.070 |
Why?
|
| Indans | 2 | 2012 | 96 | 0.070 |
Why?
|
| Papillomaviridae | 1 | 1992 | 1119 | 0.070 |
Why?
|
| Radionuclide Imaging | 3 | 2015 | 2030 | 0.070 |
Why?
|
| Microscopy, Electron | 1 | 2009 | 2645 | 0.070 |
Why?
|
| Weight Loss | 1 | 2017 | 2622 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3871 | 0.070 |
Why?
|
| Pilot Projects | 4 | 2019 | 8321 | 0.070 |
Why?
|
| Autopsy | 2 | 2023 | 1021 | 0.070 |
Why?
|
| Facial Expression | 1 | 2009 | 508 | 0.070 |
Why?
|
| Polysomnography | 1 | 2012 | 1775 | 0.060 |
Why?
|
| Massachusetts | 4 | 2021 | 8663 | 0.060 |
Why?
|
| Culture | 1 | 2009 | 633 | 0.060 |
Why?
|
| Epilepsy | 1 | 2020 | 3310 | 0.060 |
Why?
|
| Health Services Research | 1 | 2012 | 1836 | 0.060 |
Why?
|
| Menopause | 2 | 2023 | 1626 | 0.060 |
Why?
|
| Publishing | 1 | 2011 | 833 | 0.060 |
Why?
|
| Radiography | 4 | 2013 | 7022 | 0.060 |
Why?
|
| Cerebrovascular Circulation | 5 | 2007 | 2732 | 0.060 |
Why?
|
| Carbon Isotopes | 2 | 2016 | 469 | 0.060 |
Why?
|
| Monocytes | 1 | 2013 | 2594 | 0.060 |
Why?
|
| Neuronal Plasticity | 1 | 2012 | 1422 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 2737 | 0.060 |
Why?
|
| Boston | 3 | 2023 | 9311 | 0.060 |
Why?
|
| Proteins | 2 | 2014 | 6101 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 9438 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2016 | 3750 | 0.060 |
Why?
|
| Anti-HIV Agents | 2 | 1998 | 4256 | 0.060 |
Why?
|
| Gold | 1 | 2007 | 484 | 0.060 |
Why?
|
| Perfusion | 1 | 2007 | 1359 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2023 | 23404 | 0.050 |
Why?
|
| Registries | 4 | 2022 | 8090 | 0.050 |
Why?
|
| Haplotypes | 2 | 2020 | 2781 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 2 | 2018 | 977 | 0.050 |
Why?
|
| Frontal Lobe | 2 | 2017 | 1407 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2016 | 2776 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 11732 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 1125 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 5853 | 0.050 |
Why?
|
| Exercise | 1 | 2018 | 5615 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 12075 | 0.050 |
Why?
|
| DNA | 4 | 2012 | 7303 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2016 | 3509 | 0.050 |
Why?
|
| Nanostructures | 1 | 2007 | 551 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2007 | 1169 | 0.050 |
Why?
|
| Muscarinic Antagonists | 1 | 2001 | 137 | 0.050 |
Why?
|
| Lorazepam | 1 | 2001 | 145 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 10949 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2021 | 6601 | 0.050 |
Why?
|
| ROC Curve | 3 | 2014 | 3527 | 0.050 |
Why?
|
| Nanotechnology | 1 | 2007 | 710 | 0.050 |
Why?
|
| Carotid Artery, Common | 1 | 2022 | 183 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2017 | 2886 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2011 | 2715 | 0.050 |
Why?
|
| Synaptic Transmission | 1 | 2007 | 1179 | 0.050 |
Why?
|
| Data Collection | 2 | 2023 | 3340 | 0.050 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 12355 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2020 | 245 | 0.040 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2000 | 94 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 2 | 1992 | 3712 | 0.040 |
Why?
|
| Nucleoproteins | 1 | 1980 | 115 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 12244 | 0.040 |
Why?
|
| HIV Infections | 5 | 2000 | 16718 | 0.040 |
Why?
|
| Canada | 2 | 2017 | 2065 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2006 | 2539 | 0.040 |
Why?
|
| Latin America | 1 | 2020 | 381 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2001 | 390 | 0.040 |
Why?
|
| Carotid Artery, Internal | 1 | 2022 | 445 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2001 | 2032 | 0.040 |
Why?
|
| Hormones | 1 | 2023 | 887 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2006 | 1167 | 0.040 |
Why?
|
| Disability Evaluation | 2 | 2010 | 1828 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2021 | 579 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2011 | 3068 | 0.040 |
Why?
|
| Virus Shedding | 1 | 1998 | 108 | 0.040 |
Why?
|
| Hemorrhage | 2 | 2022 | 3461 | 0.040 |
Why?
|
| Lewy Bodies | 1 | 2018 | 137 | 0.040 |
Why?
|
| Phenanthrolines | 1 | 2017 | 55 | 0.040 |
Why?
|
| Meconium Aspiration Syndrome | 1 | 1997 | 29 | 0.040 |
Why?
|
| Personality | 1 | 2022 | 552 | 0.040 |
Why?
|
| Lactones | 1 | 2000 | 329 | 0.040 |
Why?
|
| Piperidines | 2 | 2012 | 1605 | 0.040 |
Why?
|
| Sclerosis | 1 | 2018 | 213 | 0.040 |
Why?
|
| HELLP Syndrome | 1 | 1997 | 41 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 1989 | 2136 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2014 | 2619 | 0.040 |
Why?
|
| Thiones | 1 | 2017 | 46 | 0.040 |
Why?
|
| Nucleic Acids | 1 | 1980 | 182 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2022 | 952 | 0.040 |
Why?
|
| Goals | 1 | 2022 | 706 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2021 | 359 | 0.040 |
Why?
|
| Europe | 2 | 2016 | 3339 | 0.040 |
Why?
|
| Palmitates | 1 | 2017 | 74 | 0.040 |
Why?
|
| Residence Characteristics | 2 | 2018 | 2050 | 0.040 |
Why?
|
| Endometrium | 1 | 2019 | 424 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2018 | 594 | 0.040 |
Why?
|
| Brain Stem | 1 | 2022 | 845 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 2020 | 655 | 0.030 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 1997 | 214 | 0.030 |
Why?
|
| European Union | 1 | 2017 | 158 | 0.030 |
Why?
|
| Frontotemporal Dementia | 1 | 2019 | 248 | 0.030 |
Why?
|
| Algorithms | 4 | 2021 | 13885 | 0.030 |
Why?
|
| Microglia | 2 | 2015 | 1266 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 647 | 0.030 |
Why?
|
| Body Height | 1 | 2022 | 1576 | 0.030 |
Why?
|
| France | 1 | 2017 | 517 | 0.030 |
Why?
|
| Family Health | 2 | 2016 | 1282 | 0.030 |
Why?
|
| Lysosomes | 1 | 2020 | 893 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 1223 | 0.030 |
Why?
|
| Voluntary Health Agencies | 1 | 2014 | 39 | 0.030 |
Why?
|
| Computers, Handheld | 1 | 2017 | 208 | 0.030 |
Why?
|
| Spain | 1 | 2016 | 465 | 0.030 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 1995 | 65 | 0.030 |
Why?
|
| Monte Carlo Method | 2 | 2014 | 1254 | 0.030 |
Why?
|
| Urinary Bladder Diseases | 1 | 1995 | 166 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 1995 | 212 | 0.030 |
Why?
|
| Electroencephalography | 2 | 2020 | 6150 | 0.030 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2014 | 90 | 0.030 |
Why?
|
| Melanocytes | 1 | 2018 | 515 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1998 | 780 | 0.030 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 1997 | 306 | 0.030 |
Why?
|
| Health Education | 2 | 1991 | 1055 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2020 | 975 | 0.030 |
Why?
|
| Drug and Narcotic Control | 1 | 2014 | 146 | 0.030 |
Why?
|
| Hemosiderin | 1 | 2013 | 43 | 0.030 |
Why?
|
| HIV Seroprevalence | 1 | 1993 | 86 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 6535 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1998 | 1043 | 0.030 |
Why?
|
| Prenatal Care | 2 | 1991 | 1092 | 0.030 |
Why?
|
| Polymerization | 1 | 2014 | 164 | 0.030 |
Why?
|
| HLA-D Antigens | 1 | 2013 | 134 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2015 | 250 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 2014 | 344 | 0.030 |
Why?
|
| Medication Systems, Hospital | 1 | 2013 | 158 | 0.030 |
Why?
|
| Osteoarthritis | 1 | 2000 | 1036 | 0.030 |
Why?
|
| Viremia | 1 | 1996 | 736 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 425 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2013 | 165 | 0.030 |
Why?
|
| Ileum | 1 | 1995 | 565 | 0.030 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2012 | 141 | 0.030 |
Why?
|
| Academies and Institutes | 1 | 2014 | 317 | 0.030 |
Why?
|
| Reoperation | 1 | 2002 | 4203 | 0.030 |
Why?
|
| Eicosanoids | 2 | 1991 | 279 | 0.030 |
Why?
|
| Leukotrienes | 1 | 1994 | 255 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 2019 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 1076 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2017 | 1997 | 0.030 |
Why?
|
| Diffusion | 1 | 2014 | 833 | 0.030 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 1992 | 77 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 1997 | 971 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 12961 | 0.030 |
Why?
|
| Pedigree | 1 | 2019 | 4648 | 0.030 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2011 | 28 | 0.030 |
Why?
|
| Orientation | 1 | 2013 | 327 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 1864 | 0.030 |
Why?
|
| Leukotriene B4 | 1 | 1992 | 294 | 0.020 |
Why?
|
| Forecasting | 1 | 2020 | 2949 | 0.020 |
Why?
|
| Memantine | 1 | 2012 | 100 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1993 | 392 | 0.020 |
Why?
|
| Demography | 1 | 2016 | 1656 | 0.020 |
Why?
|
| Pandemics | 2 | 2022 | 8387 | 0.020 |
Why?
|
| Cyclosporins | 1 | 1991 | 220 | 0.020 |
Why?
|
| Dopamine Agents | 1 | 2012 | 189 | 0.020 |
Why?
|
| Dextrans | 1 | 2013 | 595 | 0.020 |
Why?
|
| Research | 1 | 2020 | 1999 | 0.020 |
Why?
|
| Anisotropy | 1 | 2014 | 1265 | 0.020 |
Why?
|
| Body Burden | 1 | 2011 | 158 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 1708 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 2078 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1992 | 1375 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 163 | 0.020 |
Why?
|
| snRNP Core Proteins | 1 | 1989 | 22 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 905 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2014 | 1217 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2013 | 601 | 0.020 |
Why?
|
| Administration, Topical | 1 | 1992 | 689 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 2576 | 0.020 |
Why?
|
| Delusions | 1 | 2012 | 300 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 1888 | 0.020 |
Why?
|
| Cocaine | 1 | 2015 | 1007 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 20123 | 0.020 |
Why?
|
| Edema | 1 | 2014 | 790 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 950 | 0.020 |
Why?
|
| Cysteine | 1 | 1994 | 874 | 0.020 |
Why?
|
| Exercise Test | 1 | 2016 | 2075 | 0.020 |
Why?
|
| Lasers | 1 | 1993 | 952 | 0.020 |
Why?
|
| Authorship | 1 | 2011 | 271 | 0.020 |
Why?
|
| HIV-1 | 2 | 1998 | 6938 | 0.020 |
Why?
|
| Hepacivirus | 1 | 1996 | 1379 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 1989 | 898 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 2335 | 0.020 |
Why?
|
| Infant, Premature | 1 | 1997 | 2044 | 0.020 |
Why?
|
| Perception | 1 | 2015 | 1198 | 0.020 |
Why?
|
| Gadolinium | 1 | 2013 | 952 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 1989 | 694 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1993 | 624 | 0.020 |
Why?
|
| Mice | 3 | 2023 | 81178 | 0.020 |
Why?
|
| Internet | 1 | 2020 | 3063 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1989 | 2255 | 0.020 |
Why?
|
| Citric Acid Cycle | 1 | 1968 | 232 | 0.020 |
Why?
|
| Cold Temperature | 1 | 1990 | 774 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 4188 | 0.020 |
Why?
|
| Computational Biology | 1 | 2019 | 3523 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2014 | 7730 | 0.020 |
Why?
|
| Home Care Services | 1 | 2013 | 606 | 0.020 |
Why?
|
| Brain Concussion | 1 | 2018 | 1320 | 0.020 |
Why?
|
| RNA | 1 | 2017 | 2749 | 0.020 |
Why?
|
| Paired-Associate Learning | 1 | 2006 | 52 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2014 | 1548 | 0.020 |
Why?
|
| Software | 1 | 2021 | 4442 | 0.020 |
Why?
|
| Pregnancy | 6 | 1998 | 29142 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2014 | 1058 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 6172 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1989 | 1682 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2011 | 764 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1992 | 1462 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 1993 | 1195 | 0.020 |
Why?
|
| Shock | 1 | 1968 | 318 | 0.020 |
Why?
|
| Pneumonia | 1 | 1997 | 2134 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 1737 | 0.020 |
Why?
|
| New York City | 3 | 1993 | 710 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1997 | 2408 | 0.020 |
Why?
|
| Diagnostic Imaging | 2 | 2012 | 3508 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2004 | 6882 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5180 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2015 | 2266 | 0.020 |
Why?
|
| Comorbidity | 1 | 2019 | 10387 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4463 | 0.020 |
Why?
|
| Nurses | 1 | 2014 | 2461 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1993 | 1472 | 0.020 |
Why?
|
| Visual Perception | 1 | 2013 | 1420 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 1782 | 0.020 |
Why?
|
| Glycolysis | 1 | 1968 | 826 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 2007 | 1456 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2007 | 931 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 3646 | 0.010 |
Why?
|
| Observer Variation | 1 | 2010 | 2593 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2011 | 3913 | 0.010 |
Why?
|
| Alzheimer Vaccines | 1 | 2003 | 25 | 0.010 |
Why?
|
| Child | 3 | 2019 | 77679 | 0.010 |
Why?
|
| Infant, Newborn | 3 | 1998 | 25618 | 0.010 |
Why?
|
| Asthma | 2 | 1994 | 6011 | 0.010 |
Why?
|
| Materials Testing | 1 | 2007 | 867 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2017 | 4289 | 0.010 |
Why?
|
| Wakefulness | 1 | 2010 | 1245 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 9647 | 0.010 |
Why?
|
| Particle Size | 1 | 2007 | 1642 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2003 | 311 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 4328 | 0.010 |
Why?
|
| Program Evaluation | 1 | 1991 | 2486 | 0.010 |
Why?
|
| Motor Cortex | 1 | 2009 | 986 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 2234 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2015 | 10250 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2012 | 3494 | 0.010 |
Why?
|
| Problem Solving | 1 | 2004 | 440 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2014 | 6196 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2012 | 2752 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2016 | 13036 | 0.010 |
Why?
|
| Diclofenac | 1 | 2000 | 71 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 12805 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 2006 | 1016 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 9735 | 0.010 |
Why?
|
| Glucose | 1 | 2012 | 4396 | 0.010 |
Why?
|
| Biopsy | 1 | 1992 | 6757 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1992 | 8628 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2015 | 8551 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 5396 | 0.010 |
Why?
|
| Photochemistry | 1 | 1980 | 238 | 0.010 |
Why?
|
| Models, Biological | 2 | 2013 | 9582 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1998 | 112 | 0.010 |
Why?
|
| Ibuprofen | 1 | 2000 | 235 | 0.010 |
Why?
|
| Incidence | 2 | 2013 | 20945 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 1792 | 0.010 |
Why?
|
| Oropharynx | 1 | 1998 | 127 | 0.010 |
Why?
|
| Sulfones | 1 | 2000 | 437 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 1998 | 277 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2003 | 1607 | 0.010 |
Why?
|
| Urine | 1 | 1998 | 370 | 0.010 |
Why?
|
| Uterine Hemorrhage | 1 | 1998 | 255 | 0.010 |
Why?
|
| Pons | 1 | 1997 | 245 | 0.010 |
Why?
|
| DNA Ligases | 1 | 1996 | 80 | 0.010 |
Why?
|
| Nucleosomes | 1 | 1980 | 494 | 0.010 |
Why?
|
| Mesencephalon | 1 | 1997 | 329 | 0.010 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 1997 | 406 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1980 | 1060 | 0.010 |
Why?
|
| Binding Sites | 1 | 2003 | 6116 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1998 | 732 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1995 | 440 | 0.010 |
Why?
|
| Amygdala | 1 | 2001 | 1315 | 0.010 |
Why?
|
| Leukotriene Antagonists | 1 | 1994 | 127 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 1997 | 850 | 0.010 |
Why?
|
| Colposcopy | 1 | 1993 | 144 | 0.010 |
Why?
|
| Iofetamine | 1 | 1992 | 20 | 0.010 |
Why?
|
| Counseling | 2 | 1991 | 1523 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1998 | 2559 | 0.010 |
Why?
|
| Equipment Safety | 1 | 1993 | 264 | 0.010 |
Why?
|
| Accidents | 1 | 1993 | 164 | 0.010 |
Why?
|
| Nasal Septum | 1 | 1993 | 127 | 0.010 |
Why?
|
| Chlamydia trachomatis | 1 | 1993 | 246 | 0.010 |
Why?
|
| Perineum | 1 | 1993 | 211 | 0.010 |
Why?
|
| Finger Injuries | 1 | 1993 | 139 | 0.010 |
Why?
|
| Amphetamines | 1 | 1992 | 148 | 0.010 |
Why?
|
| Thalamus | 1 | 1997 | 1024 | 0.010 |
Why?
|
| Thromboxane B2 | 1 | 1991 | 152 | 0.010 |
Why?
|
| Women's Health | 2 | 1991 | 2034 | 0.010 |
Why?
|
| Calcimycin | 1 | 1990 | 222 | 0.010 |
Why?
|
| Syphilis | 1 | 1993 | 227 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 35129 | 0.010 |
Why?
|
| Bronchial Provocation Tests | 1 | 1990 | 227 | 0.010 |
Why?
|
| Urban Health | 1 | 1993 | 547 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1993 | 579 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1997 | 1782 | 0.010 |
Why?
|
| Renal Circulation | 1 | 1991 | 333 | 0.010 |
Why?
|
| Respiratory System | 1 | 1994 | 557 | 0.010 |
Why?
|
| Cerebellum | 1 | 1997 | 1490 | 0.010 |
Why?
|
| Bronchoconstriction | 1 | 1990 | 143 | 0.010 |
Why?
|
| Gestational Age | 1 | 1998 | 3493 | 0.010 |
Why?
|
| Humidity | 1 | 1990 | 197 | 0.010 |
Why?
|
| Chlamydia Infections | 1 | 1993 | 365 | 0.010 |
Why?
|
| Ambulatory Care | 2 | 1991 | 2708 | 0.010 |
Why?
|
| Histones | 1 | 1980 | 2600 | 0.010 |
Why?
|
| Social Work | 1 | 1991 | 162 | 0.010 |
Why?
|
| Gonorrhea | 1 | 1993 | 335 | 0.010 |
Why?
|
| Cesarean Section | 1 | 1997 | 1365 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1991 | 455 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1992 | 1032 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 7326 | 0.000 |
Why?
|
| Protein Binding | 1 | 1980 | 9392 | 0.000 |
Why?
|
| RNA, Viral | 1 | 1996 | 2902 | 0.000 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1991 | 525 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 10182 | 0.000 |
Why?
|
| Creatinine | 1 | 1991 | 1919 | 0.000 |
Why?
|
| Capillaries | 1 | 1968 | 774 | 0.000 |
Why?
|
| Endothelium, Vascular | 1 | 1997 | 4455 | 0.000 |
Why?
|
| Base Sequence | 1 | 1996 | 12801 | 0.000 |
Why?
|
| Liver | 1 | 1980 | 7472 | 0.000 |
Why?
|
| Rats | 1 | 1980 | 24273 | 0.000 |
Why?
|
| Glomerular Filtration Rate | 1 | 1991 | 2170 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 18116 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1968 | 2025 | 0.000 |
Why?
|
| Sexual Behavior | 1 | 1991 | 2056 | 0.000 |
Why?
|
| Social Support | 1 | 1991 | 2117 | 0.000 |
Why?
|
| Neoplasms | 1 | 1989 | 21672 | 0.000 |
Why?
|
| Poverty | 1 | 1991 | 2660 | 0.000 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1991 | 3923 | 0.000 |
Why?
|
| Kidney | 1 | 1991 | 7183 | 0.000 |
Why?
|
| Hypertension | 1 | 1991 | 8480 | 0.000 |
Why?
|